Tempest Boosts Leadership With Sheldon Mullins As New VP Of Regulatory Affairs

Tempest Therapeutics, Inc., a biotech company focused on pioneering targeted and immune-driven cancer therapies, has appointed Sheldon Mullins as the new Vice President of Regulatory Affairs. This move follows the recent hiring of Troy Wagner as Vice President of Quality Assurance, who brings significant expertise in late-stage drug development. In line with their efforts to advance the pivotal study of amezalpat in first-line HCC patients, Darrin Bomba and Henry Johnson have also been promoted to Vice President of Development Operations and Vice President of CMC & Medicinal Chemistry, respectively, to better reflect their roles in advancing the company’s late-stage initiatives.

Sheldon Mullins took on the role of Vice President of Regulatory Affairs at Tempest in September 2024, bringing with him over 25 years of experience in regulatory affairs. His expertise spans the entire drug development process, from pre-IND stages to post-approval activities across various therapeutic areas. Before joining Tempest, Mr. Mullins served in regulatory leadership positions at Arrowhead Pharmaceuticals and Ardelyx, Inc. Earlier in his career, he held key regulatory roles at companies such as Anacor Pharmaceuticals, Onyx Pharmaceuticals, and Genentech. He holds a Master of Science in Business Analysis from San Francisco State University and a Bachelor’s in Chemistry from Sonoma State University.

Stephen Brady, president and chief executive officer of Tempest, said in a statement, “The expansion of our leadership team with deeply experienced members strengthens our global clinical capabilities as we transition to a late clinical company. Sheldon’s extensive experience in leading regulatory efforts for early- and late-stage drug candidates will be invaluable as we move into Phase 3 development of amezalpat to treat first-line hepatocellular carcinoma.”

Mr. Mullins commented, “I am thrilled to join Tempest at such an exciting time as the team prepares to advance amezalpat into a pivotal study. Amezalpat has demonstrated very strong results in the treatment of first-line liver cancer, and I am eager to contribute to the team’s efforts to bring this potential life-saving therapy to patients.”